Adjuvant and neoadjuvant therapy for pancreatic cancer
Abstract. Pancreatic cancer still remains a major cause of cancer-related mortality; however, there is a slight but continuous improvement in survival over the past 2 decades. Progress in chemotherapy has contributed to the survival improvement in patients with any stage of pancreatic cancer. In thi...
Main Authors: | Shimpei Maeda, MD, PhD, Michiaki Unno, MD, PhD, FACS, Jun Yu, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2019-09-01
|
Series: | Journal of Pancreatology |
Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000028 |
Similar Items
-
Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
by: Chen Liu MD, PhD, et al.
Published: (2020-04-01) -
Efficacy and Safety of Huaier Granule as an Adjuvant Therapy for Cancer: An Overview of Systematic Reviews and Meta-Analyses
by: Jixin Chen MD, et al.
Published: (2022-03-01) -
Interplay of Oncoplastic Reconstruction and Adjuvant Radiation Therapy in Breast Cancer
by: Ryan T. Morse, MD, et al.
Published: (2024-03-01) -
Narrowing Racial Gaps in Breast Cancer: Factors Affecting Probability of Adjuvant Radiation Therapy
by: Felicia Snead, MD, et al.
Published: (2020-01-01) -
Potential Impact of on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score–Matched Analysis
by: Sung Hwan Lee MD, PhD, et al.
Published: (2019-02-01)